Abstract
Crohn's disease (CD) yields a considerable burden to the Spanish National Health System (NHS). Thanks to the advent of adalimumab and infliximab biosimilars (bADA, bINF), costs burden decreased substantially. However, a further assessment on additional efficiencies is warranted. The NHS’s Willingness to Pay (WTP) per additional Quality Adjusted Life Year (QALY) could be considered an important metric to assess.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
